US-based NeoChord, a developer of minimally invasive technology for the treatment of degenerative mitral regurgitation, has received $850,000 of a possible $7m in series B equity financing.
Venture capital firm Hopen Life Science Ventures and existing investors provided the company’s $5.1m B round last year. The company is alsp backed by CHV Capital, formerly known as Clarian Health Ventures, which invests on behalf of the Indiana University Health, Indiana’s largest healthcare system,
In 2009 NeoChord raised $3.5m in A funding from CHV Capital, and venture firms Cedar Point Capital, Heron Capital, South Metro Investors, TGap Ventures, Twilight Venture Partners and Two Rivers Angel Investment, a Member of the RAIN Fund Network.
NeoChord has exclusive rights to state-of-the-art ‘augmented reality’ imaging technology from the Robarts Research Institute (RRI) at Western University Canada.